CDMO– tag –
-
US Policy Shift Reshapes Biomanufacturing Supply Chain: Fujifilm Diosynth, Japan Government Drive Asia’s Rise as Key Hub
BioProcess Insider USA Overview The U.S. policy pivot regarding China's biotechnology sector is driving a global biomanufacturing supply chain restructuring. Fujifilm Diosynth Biotechnologies is pursuing over $4 billion in global expansi... -
Lonza, Samsung Biologics, and Catalent Lead 2026 Biologics CDMO Market, Driven by AI Manufacturing & APAC Expansion
Towards Healthcare Unknown Overview Lonza, Samsung Biologics, and Catalent are identified as key players leading the 2026 biologics CDMO market. Lonza excels in end-to-end multi-modality and scientific innovation, Samsung Biologics in la... -
AGC Biologics Secures CDMO Contract with Teikoku Seiyaku for Recombinant rhMMP-7 Drug Substance, GMP Production at Chiba Plant
AGC Biologics Japan Overview AGC Biologics has signed a CDMO contract with Teikoku Seiyaku Co. for the microbial drug substance manufacturing of recombinant human matrix metalloproteinase-7 (rhMMP-7) 'KTP-001'. Initial cell bank creation... -
Global Biomanufacturing Leaders Lonza, Fujifilm Diosynth, AGC Biologics Expand CGT & mRNA Capacities
Healthcare Ranking USA Overview Major CDMOs including Lonza, Fujifilm Diosynth Biotechnologies, and AGC Biologics are aggressively expanding global manufacturing capacities for biologics, cell & gene therapies (CGT), and mRNA product... -
Aurobindo Pharma Inaugurates ₹10 Billion (USD 120M) TheraNym Biologics CDMO Plant in India, Expanding Capacity by 25,000L
Sahi India Overview Aurobindo Pharma announced the inauguration of its state-of-the-art ₹10 billion (approx. USD 120 million) TheraNym biologics CDMO facility in Hyderabad, India. This plant adds 25,000 liters of mammalian cell culture c... -
CordenPharma Announces Multi-Million Dollar Expansion of Oligonucleotide Manufacturing to Meet Soaring Demand for Nucleic Acid-Based Medicines
Pharmaceutical Technology Europe Overview CordenPharma announced a multi-million dollar investment to significantly expand its oligonucleotide manufacturing capacity across its global network. This strategic expansion aims to meet the in... -
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ... -
Samsung Biologics Secures Multi-Year mRNA Vaccine CDMO Partnership with Major Pharma, Leading Market Expansion
Business Korea South Korea Overview Samsung Biologics has reportedly secured a multi-year contract for large-scale mRNA vaccine manufacturing with a global pharmaceutical company. This new partnership further solidifies Samsung Biologics... -
Lonza Significantly Expands Biologics Manufacturing Capacity by Over 200,000 Liters with New Swiss Facility
Lonza Press Release Switzerland Overview Lonza announced the operational launch of a state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capabilities. This expansion adds over 2... -
Fujifilm Reshuffles Life Sciences Leadership and Opens New Facility to Quadruple iPSC Manufacturing Capacity
FUJIFILM Holdings America Corporation Press Release USA Overview FUJIFILM Holdings America Corporation announced a reshuffle in the leadership of its life sciences group, with Delara Motlagh appointed as President and COO of FUJIFILM Cel...
